Aradigm, Novo Nordisk expand diabetes deal

ARDM and NVO again expanded their diabetes deal, resulting in payments of $27.5 million to ARDM, including $12 million for IP related to inhaled insulin. ARDM will retain exclusive, royalty-free right...